Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biota Pharmaceuticals Inc    NABI

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 9,55 M
EBIT 2017 -29,3 M
Net income 2017 -31,2 M
Debt 2017 -
Yield 2017 -
Sales 2018 5,50 M
EBIT 2018 -32,6 M
Net income 2018 -33,2 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 1,98x
Capi. / Sales2018 3,43x
Capitalization 18,9 M
More Financials
Company
Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections.Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics, currently being evaluated in ongoing Phase 2b SPIRITUS... 
More about the company
Surperformance© ratings of Biota Pharmaceuticals Inc
Trading Rating : - Investor Rating :
More Ratings
Latest news on BIOTA PHARMACEUTICALS INC
05/08 AVIRAGEN THERAPEUTICS, INC. : Management's Discussion and Analysis of Financial ..
05/04 AVIRAGEN THERAPEUTICS, INC. (NASDAQ : AVIR) Files An 8-K Results of Operations a..
05/04 AVIRAGEN THERAPEUTICS, INC. : Results of Operations and Financial Condition, Fin..
05/04 Aviragen Therapeutics Reports Third Quarter Fiscal Year 2017 Financial Result..
04/05 AVIRAGEN THERAPEUTICS INC : Blog Coverage Aviragen to Explore Strategic Alternat..
04/04 AVIRAGEN THERAPEUTICS (NASDAQ : AVIR) Files An 8-K Departure of Directors or Cer..
04/04 AVIRAGEN THERAPEUTICS, INC. : Change in Directors or Principal Officers, Other E..
04/04 Aviragen Therapeutics Announces Review of Strategic Alternatives and Provides..
04/03 AVIRAGEN THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Contin..
02/14 AVIRAGEN THERAPEUTICS (NASDAQ : AVIR) Files An 8-K Other Events
More news
Sector news : Bio Therapeutic Drugs
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
More sector news : Bio Therapeutic Drugs
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 3
Average target price 4,17 $
Spread / Average Target 753%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph M. Patti President, CEO & Executive Director
Russell H. Plumb Executive Chairman
Mark P. Colonnese Chief Financial Officer & Executive Vice President
John H. Vernachio Vice President-Preclinical Development
Geoffrey F. Cox Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOTA PHARMACEUTICALS ..19
AMGEN, INC.6.02%113 994
CELGENE CORPORATION0.86%91 185
GILEAD SCIENCES, INC.-9.93%84 284
REGENERON PHARMACEUTIC..24.14%48 380
ACTELION LTD26.30%30 602
More Results